Tokushima University / Educator and Researcher Directory --- Fukuda, Shoichiro

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Shoichiro Fukuda, Haruka Takata, Ryo Hayashi, Haruka Yamamoto, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto, Shingo Kobayashi, Hidenori ANDO and Tatsuhiro Ishida : Ionic Liquids Composed of Lactic Acid and Trometamol Enhance the Oral Absorption of 10 kDa Dextran, as a Model Compound of Mid-Sized Molecules, Biological & Pharmaceutical Bulletin, 49, 1, 141-148, 2026. (Summary) Oral administration is the preferred route for drug administration owing to a high level of patient compliance and suitability for long-term treatment. However, drugs with a molecular weight of >1000 Da such as peptide-based therapeutics generally exhibit poor absorption from the gastrointestinal tract. In this study, we evaluated the potential of ionic liquids to enhance the oral absorption of mid-sized molecules such as dextran, which has a size of 10 kDa. In this study, the ionic liquids we tested enhanced the oral absorption of 10 kDa mid-sized dextran. Among the ionic liquids we tested, d/l-Lactic acid-trometamol ([Lac][Tris])-based ionic liquids consistently yielded higher values for maximum concentration (C_max; 153.9 ± 11.0 nmol/L) of dextran as well as for the area under the curve representing 0-2 h (AUC_{0-2 h}; 228.9 ± 54.1 nmol × h/L) compared with that of the other ionic liquids tested. The [Lac][Tris] = 5 : 1 ionic liquid achieved relatively higher values for both C_max and AUC_{0-2 h}. Interestingly, the observed oral absorption enhancement effect by the [Lac][Tris] = 5 : 1 ionic liquid for mid-sized molecules depended on the concentration of dextran (10 kDa). These results show that ionic liquid formulations can overcome the intestinal barrier and lead to systemic absorption of mid-sized molecules with molecular weights. Although further optimizations aimed at translating ionic liquid technology to the oral delivery of peptide drugs must be required, our results could expand the utility and possibility of ionic liquids as an oral absorption enhancer for mid-sized molecules such as peptides. (Keyword) intestinal absorption / ionic liquid / mid-sized molecule / oral administration (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b25-00668 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 41565278 ● Summary page in Scopus @ Elsevier: 2-s2.0-105028179972 (DOI: 10.1248/bpb.b25-00668, PubMed: 41565278, Elsevier: Scopus)
2.	Shunji Abe, Haruka Takata, Taro Shimizu, Yoshino Kawaguchi, Shoichiro Fukuda, Haruka Yamamoto, Hidenori ANDO and Tatsuhiro Ishida : Impact of pre-existing anti-polyethylene glycol (PEG) IgM on biodistribution and humoral response of intramuscularly administered PEGylated mRNA loaded lipid nanoparticle, Journal of Controlled Release, 383, 113821, 2025. (Summary) With the approval of mRNA vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), lipid nanoparticles (LNP) have emerged as a powerful tool for nucleic acid delivery. Modification of LNP with polyethylene glycol (PEG)-lipids contributes to their in vitro and in vivo stability by reducing aggregation of the particles. Despite the general acknowledgement of the low immunogenicity of PEG, there are numerous reports of the occurrence of anti-PEG antibodies in the blood of healthy individuals. Furthermore, there are reports that pre-existing anti-PEG IgM antibodies attenuated the efficacy of PEG-modified drugs administered systemically. Skeletal muscles, the administration site for mRNA vaccines, are highly vascularized by a network of blood vessels to provide them with nutrients and oxygen. Since skeletal muscles can contain circulating anti-PEG antibodies or the administered mRNA-LNP extravasate into bloodstream, the purpose of this study was to evaluate the effects of pre-existing anti-PEG IgM on the protein translation, biodistribution, and humoral responses to mRNA-loaded LNP (mRNA-LNP) administered intramuscularly (i.m.) in mice. We found that the presence of anti-PEG IgM in blood has only a minor effect on the translation and distribution of mRNA-LNP in the localized muscle area where the mRNA-LNP were administered. Circulating anti-PEG IgM did not increase the total accumulation of mRNA-LNP in the liver, but did markedly diminish its protein translation because the mRNA-LNP were delivered primarily to Kupffer cells rather than to hepatocytes. Binding of anti-PEG IgM to mRNA-LNP, and subsequent complement activation, suppressed mRNA translation loaded in LNP in the liver. Repeated intramuscular injections of SARS-CoV-2 Spike protein mRNA-LNP elicited a robust immune response. Our results indicate that the presence of circulating anti-PEG IgM does not interfere with the efficiency of mRNA vaccines administered i.m. in mice. We can speculate that non-specific translation of mRNA vaccines in somatic cells may be inhibited in vivo by circulating anti-PEG IgM, reducing adverse effects such as hepatitis and myocarditis that are caused by immune responses against translated antigen proteins. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2025.113821 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40339658 ● Search Scopus @ Elsevier (PMID): 40339658 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jconrel.2025.113821 (DOI: 10.1016/j.jconrel.2025.113821, PubMed: 40339658)

Proceeding of International Conference:

1.	I Tanaka, H Itoigawa, K Hori, Shoichiro Fukuda, H Heng, Haruka Takata, T Kato, M Sato, Y Sekido, S Shimizu, Tatsuhiro Ishida, T Yoshikawa and M Ishii : OXTR-targeted local therapy could be a promising strategy for pleural mesothelioma, AACR Annual Meeting 2026, San Diego, Apr. 2026.
2.	Mei Morikawa, Shoichiro Fukuda, Chiho Shinozaki, Daiki Sasagawa, Haruka Takata, Takeshi Nakae, Hidetoshi Hamamoto, Hidenori ANDO, Masaya Denda, Yosuke Matsushita, Tetsuro Yoshimaru, Toyomasa Katagiri, Akira Otaka and Tatsuhiro Ishida : Development of transdermal absorption enhancement technology for breast cancer growth inhibitory peptide with ionic liquids, The 4th Korea-Japan Young Scientists Workshop on Pharmaceutics, Seoul, Jun. 2025.
3.	Shoichiro Fukuda, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto, Hidenori ANDO and Tatsuhiro Ishida : Ionic liquids improve intestinal absorption of macromolecules (< 20 kDa): their effects on gastrointestinal cellular tight junctions and absorption sites, 17th International Symposium on Nanomedicine, Nagoya, Dec. 2024.
4.	Shoichiro Fukuda, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto, Hidenori ANDO and Tatsuhiro Ishida : Enhanced effect of ionic liquid on intestinal absorption of macromolecules (< 10 kDa), 39th JSSX and 26th North American ISSX Meeting, Hawaii, Sep. 2024.
5.	Shoichiro Fukuda, Hidenori ANDO, Chihiro Kato, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto and Tatsuhiro Ishida : Ionic liquids improve intestinal absorption of macromolecules of lower molecular weights, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
6.	Shoichiro Fukuda, Hidenori ANDO, Chihiro Kato, Haruka Takata, T Nakae, N Tatsumi, H Hamamoto and Tatsuhiro Ishida : The molecular weight limitation on increased intestinal absorption by ionic liquids, 16th International Symposium on Nanomedicine, Osaka, Nov. 2023.
7.	Shoichiro Fukuda, Hidenori ANDO, Atsuya Maruyama, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : The mechanism investigation of intestinal absorption enhancement of drugs using ionic liquids, 15th International Symposium on Nanomedicine, Tokushima, Dec. 2022.

Proceeding of Domestic Conference:

1.	Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO, Shingo Kobayashi and Tatsuhiro Ishida : イオン液体を用いた中分子化合物の新規腸管吸収促進技術の開発;吸収部位選択性および安全性評価, 日本薬学会第146年会, Mar. 2026.
2.	Ryo Hayashi, Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Shingo Kobayashi, Hidenori ANDO and Tatsuhiro Ishida : イオン液体による中分子医薬品の経鼻吸収促進技術の開発:インスリンの血中移行性および有効性の評価, 日本薬学会第146年会, Mar. 2026.
3.	Yukiho Okamoto, Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Shingo Kobayashi, Hidenori ANDO and Tatsuhiro Ishida : イオン液体を用いた中分子化合物の経皮吸収促進技術に関する基礎的検討, 日本薬学会第146年会, Mar. 2026.
4.	Mei Morikawa, Shoichiro Fukuda, Chiho Shinozaki, Daiki Sasagawa, Haruka Takata, 中江崇, 濱本英利, Hidenori ANDO, Masaya Denda, Yosuke Matsushita, Tetsuro Yoshimaru, Akira Otaka, Toyomasa Katagiri and Tatsuhiro Ishida : イオン液体を用いた経皮吸収促進技術による乳がん増殖抑制ペプチド(dstERAP)の吸収改善と抗腫瘍効果の検討, 第64回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2025.
5.	Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Shingo Kobayashi, Hidenori ANDO and Tatsuhiro Ishida : イオン液体による中分子化合物の経口吸収促進技術の開発:乳酸・トロメタモール系イオン液体による吸収促進とモル比最適化, 第64回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2025.
6.	Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Shingo Kobayashi, Hidenori ANDO and Tatsuhiro Ishida : イオン液体による中分子化合物の経口吸収促進機構の解明;乳酸・トロメタモール比の最適化と密着結合タンパク質への作用, 第46回生体膜と薬物の相互作用シンポジウム, Nov. 2025.
7.	Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO, Shingo Kobayashi and Tatsuhiro Ishida : イオン液体を用いた中分子化合物の新規腸管吸収促進技術の開発, 日本薬物動態学会第40回年会, Oct. 2025.
8.	Mei Morikawa, Shoichiro Fukuda, Chiho Shinozaki, Daiki Sasagawa, Haruka Takata, 中江崇, 濱本英利, Hidenori ANDO, Masaya Denda, Yosuke Matsushita, Tetsuro Yoshimaru, Toyomasa Katagiri, Akira Otaka and Tatsuhiro Ishida : イオン液体を用いた乳癌増殖抑制ペプチドの経皮吸収促進技術の開発と抗腫瘍効果の検討, 第63回日本癌治療学会学術集会, Oct. 2025.
9.	Mei Morikawa, Shoichiro Fukuda, Chiho Shinozaki, Daiki Sasagawa, Haruka Takata, 中江崇, 濱本英利, Hidenori ANDO, Masaya Denda, Yosuke Matsushita, Tetsuro Yoshimaru, Toyomasa Katagiri, Akira Otaka and Tatsuhiro Ishida : イオン液体を用いた乳癌増殖抑制ペプチドの経皮吸収促進技術の開発と抗腫瘍効果の検討, 第13回PhysChem Forum Japan, Oct. 2025.
10.	Tatsuhiro Ishida and Shoichiro Fukuda : イオン液体を用いた中分子化合物の経口投与技術の開発, 第11回日本薬剤学会経口吸収フォーカスグループ合宿討論会, Oct. 2025.
11.	Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Shingo Kobayashi, Hidenori ANDO and Tatsuhiro Ishida : イオン液体を用いた中分子化合物の吸収促進技術の開発, 第33回DDSカンファランス, Sep. 2025.
12.	Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO, Shingo Kobayashi and Tatsuhiro Ishida : イオン液体を用いた中分子化合物の新規腸管吸収促進技術の開発, 第34回次世代医工学研究会, Jul. 2025.
13.	Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO, Shingo Kobayashi and Tatsuhiro Ishida : 経口吸収促進剤としてのイオン液体の安全性:反復経口投与による評価, 第52回日本毒性学会学術年会, Jul. 2025.
14.	Ryo Hayashi, Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Shingo Kobayashi, Hidenori ANDO and Tatsuhiro Ishida : イオン液体による中分子化合物の経鼻吸収促進技術に関する基礎的検討;イオン液体で経鼻吸収可能な分子量閾値の検討, 第41回日本DDS学会学術集会, Jun. 2025.
15.	Mei Morikawa, Shoichiro Fukuda, Chiho Shinozaki, Daiki Sasagawa, Haruka Takata, 中江崇, 濱本英利, Hidenori ANDO, Masaya Denda, Yosuke Matsushita, Tetsuro Yoshimaru, Akira Otaka, Toyomasa Katagiri and Tatsuhiro Ishida : イオン液体による乳がん増殖抑制ペプチド(dstERAP)の経皮吸収促進技術の開発に関する基礎的検討, 第41回日本DDS学会学術集会, Jun. 2025.
16.	Ryo Hayashi, Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO, Shingo Kobayashi and Tatsuhiro Ishida : イオン液体を基材として用いた中分子化合物の経鼻吸収促進技術に関する基礎的検討, 日本薬剤学会第40年会, May 2025.
17.	Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO, Shingo Kobayashi and Tatsuhiro Ishida : イオン液体を用いた中分子化合物の新規腸管吸収促進技術の開発, 日本薬剤学会第40年会, May 2025.
18.	KISO Yurika, Shoichiro Fukuda, 向井英史, Tsuyoshi Tahara, Tamaki Otani, 毛利浩太, 北原育美, 松尾礼子, 桑原宏哉, 永田哲也, 濱本英利, Tatsuhiro Ishida, 横田隆徳 and Takanori KANAZAWA : ヘテロ二本鎖核酸のNose-to-Brainデリバリーに対するNose-to-Brain送達ナノ粒子とイオン液体の有用性評価, 日本薬学会第145年会, Mar. 2025.
19.	KISO Yurika, 松尾礼子, Shoichiro Fukuda, 濱本英利, 桑原宏哉, 永田哲也, Tatsuhiro Ishida, 横田隆徳 and Takanori KANAZAWA : ヘテロ二本鎖核酸のNose-to-Brainデリバリーに向けた基礎的検討, 第63回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2024.
20.	KISO Yurika, 松尾礼子, Shoichiro Fukuda, 濱本英利, 桑原宏哉, 永田哲也, Tatsuhiro Ishida, 横田隆徳 and Takanori KANAZAWA : ポリマー/ペプチド共集合化ナノ粒子およびイオン液体併用によるヘテロ二本鎖核酸のNose-to-Brainデリバリーに向けた基礎的検討, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
21.	Mei Morikawa, Shoichiro Fukuda, Hidenori ANDO, Haruka Takata, 中江崇, 辰巳昇, 濱本英利 and Tatsuhiro Ishida : イオン液体を用いた中分子化合物の経皮吸収促進技術の開発:吸収における分子量閾値の探索, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
22.	Shoichiro Fukuda, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO and Tatsuhiro Ishida : イオン液体による中分子化合物の経口吸収促進機構の解明;消化管密着結合及び消化管吸収部位への影響, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
23.	Shoichiro Fukuda, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto, Hidenori ANDO and Tatsuhiro Ishida : Ionic liquids improve intestine absorption of macromolecules, 2024 Tokushima Bioscience Retreat, Sep. 2024.
24.	Tatsuhiro Ishida, Taro Shimizu, Shoichiro Fukuda, Haruka Takata and Hidenori ANDO : イオン液体を用いた中分子化合物の吸収促進技術の開発, 第40回日本DDS学会学術集会, Jul. 2024.
25.	Shoichiro Fukuda, Kato Chihiro, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO and Tatsuhiro Ishida : イオン液体による中分子化合物の経口吸収促進機構の解明に関する検討;消化管上皮タイトジャンクションと化合物の消化管内滞留性への影響, 日本薬剤学会第39年会, May 2024.
26.	Shoichiro Fukuda, Hidenori ANDO, Chihiro Kato, Haruka Takata, 中江崇, 辰巳昇, 濱本英利 and Tatsuhiro Ishida : イオン液体を新規吸収促進剤として用いた中分子化合物の経口吸収改善効果に関する検討, 第44回生体膜と薬物の相互作用シンポジウム, Oct. 2023.
27.	Shoichiro Fukuda, Hidenori ANDO, Chihiro Kato, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto and Tatsuhiro Ishida : The molecular weight limitation on increased intestinal absorption by ionic liquids, 日本薬物動態学会第38回年会, Sep. 2023.
28.	Shoichiro Fukuda, Hidenori ANDO, 中江崇, 辰巳昇, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : イオン液体による難吸収性中分子化合物の腸管吸収促進効果の検討, 第39回日本DDS学会学術集会, Jul. 2023.
29.	Shoichiro Fukuda, Hidenori ANDO, Maruyama Atsuya, 中江崇, 辰巳昇, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : イオン液体を基剤とした難吸収性中分子化合物の腸管吸収改善の検討, 日本薬剤学会第38年会, May 2023.
30.	Shoichiro Fukuda, Hidenori ANDO, Atsuya Maruyama, 中江崇, 辰巳昇, 濱本英利, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : イオン液体による薬物の腸管吸収促進メカニズムの検討, 第27回創剤フォーラム若手研究会, Sep. 2022.

Designated Assistant Professor : Fukuda, Shoichiro

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference: